메뉴 건너뛰기




Volumn 19, Issue 3, 2017, Pages 394-400

Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy

Author keywords

incretin therapy; MK 3102; oral antihyperglycaemic agent

Indexed keywords

AMYLASE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; OMARIGLIPTIN; PLACEBO; SITAGLIPTIN; TRIACYLGLYCEROL LIPASE; 2-(2,5-DIFLUOROPHENYL)-5-(2-(METHYLSULFONYL)-2,6-DIHYDROPYRROLO(3,4-C)PYRAZOL-5(4H)-YL)TETRAHYDRO-2H-PYRAN-3-AMINE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FUSED HETEROCYCLIC RINGS; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; PYRAN DERIVATIVE;

EID: 85010285221     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12832     Document Type: Article
Times cited : (24)

References (10)
  • 1
    • 34247362355 scopus 로고    scopus 로고
    • Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes
    • Pratley RE, Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin. 2007;23(4):919-931.
    • (2007) Curr Med Res Opin , vol.23 , Issue.4 , pp. 919-931
    • Pratley, R.E.1    Salsali, A.2
  • 2
    • 84866268783 scopus 로고    scopus 로고
    • Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    • Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.
    • (2012) Diabetes Care , vol.35 , Issue.6 , pp. 1364-1379
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3
  • 3
    • 84899522115 scopus 로고    scopus 로고
    • Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes
    • Biftu T, Sinha-Roy R, Chen P, et al. Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem. 2014;57(8):3205-3212.
    • (2014) J Med Chem , vol.57 , Issue.8 , pp. 3205-3212
    • Biftu, T.1    Sinha-Roy, R.2    Chen, P.3
  • 4
    • 0003244085 scopus 로고    scopus 로고
    • Longitudinal data analysis of continuous and discrete responses for pre-post designs
    • Liang KY, Zeger SL. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Indian J Stat. 2000;62:134-148.
    • (2000) Indian J Stat , vol.62 , pp. 134-148
    • Liang, K.Y.1    Zeger, S.L.2
  • 5
    • 0021832508 scopus 로고
    • Comparative analysis of two rates
    • Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4(2):213-226.
    • (1985) Stat Med , vol.4 , Issue.2 , pp. 213-226
    • Miettinen, O.1    Nurminen, M.2
  • 6
    • 77949416255 scopus 로고    scopus 로고
    • Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials
    • DeFronzo RA, Stonehouse AH, Han J, Wintle ME. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med. 2010;27(3):309-317.
    • (2010) Diabet Med , vol.27 , Issue.3 , pp. 309-317
    • DeFronzo, R.A.1    Stonehouse, A.H.2    Han, J.3    Wintle, M.E.4
  • 7
    • 84962439676 scopus 로고    scopus 로고
    • Safety and efficacy of omarigliptin (MK-3102), a novel once-weekly DPP-4 inhibitor for the treatment of patients with type 2 diabetes
    • Sheu WH, Gantz I, Chen M, et al. Safety and efficacy of omarigliptin (MK-3102), a novel once-weekly DPP-4 inhibitor for the treatment of patients with type 2 diabetes. Diabetes Care. 2015;38(11):2106-2114.
    • (2015) Diabetes Care , vol.38 , Issue.11 , pp. 2106-2114
    • Sheu, W.H.1    Gantz, I.2    Chen, M.3
  • 8
    • 84924042029 scopus 로고    scopus 로고
    • Effect of omarigliptin, a novel once-weekly DPP-4 inhibitor, in Japanese patients with type 2 diabetes: a placebo- and sitagliptin-controlled trial
    • Gantz I, Okamoto T, Ito Y, Okuyama K, Engel SS. Effect of omarigliptin, a novel once-weekly DPP-4 inhibitor, in Japanese patients with type 2 diabetes: a placebo- and sitagliptin-controlled trial. Diabetologia. 2014;57(S1):S55.
    • (2014) Diabetologia , vol.57 , Issue.S1 , pp. S55
    • Gantz, I.1    Okamoto, T.2    Ito, Y.3    Okuyama, K.4    Engel, S.S.5
  • 9
    • 85013764194 scopus 로고    scopus 로고
    • 2012., Accessed April 5, 2016
    • Amylin Pharmaceuticals Inc. Bydureon medical review 2011. 2012. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022200Orig1s000MedR.pdf. Accessed April 5, 2016.
    • Bydureon medical review 2011
  • 10
    • 85013823254 scopus 로고    scopus 로고
    • 2011., Accessed April 5, 2016
    • Boehringer Ingleheim Pharmaceuticals Inc. Linagliptin medical review 2010. 2011. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201280Orig1s000MedR.pdf. Accessed April 5, 2016.
    • Linagliptin medical review 2010


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.